Hepatocellular carcinoma: Updates in primary prevention
- 27 Downloads
Hepatocellular carcinoma is a significant cause of mortality worldwide and a growing problem in the United States. Treatment options are often limited, and median survival is less than 1 year. Thus, prevention may provide the best opportunity to alter the natural history of this disease. Primary prevention is best exemplified by the successes of such public health measures as universal hepatitis B vaccination. Such antiviral therapies as interferon may also have a role. Lessons can be learned from complementary and alternative medicine. Nevertheless, more work is needed in understanding hepatocarcinogenesis and in developing models to assess potential chemopreventive agents.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.El-Serag HB, Davila J, Petersen N: The incidence of hepatocellular carcinoma in the United States: Is it still rising? Gastroenterology 2003, 124(Suppl 1):A-690.Google Scholar
- 6.Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339–46. A compact up-to-date review of what is known about hepatocarcinogenesis. A better understanding of the mechanisms of HCC development is essential to progress in prevention of HCC.PubMedCrossRefGoogle Scholar
- 15.Huang K, Lin S: Nationwide vaccination: a success story in Taiwan. Vaccine 2000, 18(Suppl 1):S34-S38.Google Scholar
- 23.Centers for Disease Control and Prevention. http://ww.cdc.gov/ncidod/diseases/hepatitis/c/faq.htm#6b Accessed September 30, 2003.Google Scholar
- 26.Shiratoi Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.Google Scholar
- 35.Bacon BR, Di Bisceglie AM: Hereditary hemochromatosis. In Liver Disease: Diagnosis and Management. Edited by Bacon BR.New York: Churchill Livingstone; 2000:140–149.Google Scholar